GTx rallies as company set to present data from trial misses at conference

|By:, SA News Editor

Shares of GTx (GTXI +9%) are trading notably higher.

The company said today it will present top line results from POWER1 and POWER2 at the European Cancer Congress.

The Phase 3 trials evaluated enobosarm as a treatment for muscle wasting in patients with non-small cell lung cancer.

It's perhaps worth noting here that these trials did not meet their pre-specified criteria, news that, when released back on August 19, sent GTXI tumbling some 65%.